A retrospective study on the association between ABO blood group and the severity and prognosis of hospitalized Chinese patients with COVID-19 Authors: Yongjie Xu, Jinjin Yang, Zhaopei Guo, Weiquan You, Aizhu Ye, Luoli Yu, Lin Lin, Fengling Fang, Hongyan Guo, Dongbiao Qiu, Jianwen Xu, Ya Fu Published: 2025 ABSTRACT BackgroundThe outbreak of the novel coronavirus (SARS-CoV-2) has led to a severe public health crisis worldwide, significantly impacting human lives and health. The clinical manifestations and severity of COVID-19 vary among individuals, influenced by factors such as lifestyle, underlying health conditions, and genetic predispositions. Among these factors, blood type has garnered considerable attention as a potential biological marker that may affect both the risk of SARS-CoV-2 infection and disease severity.MethodsThis retrospective study analyzed hospitalized COVID-19 patients at Fujian Medical University First Hospital from December 1, 2022, to January 31, 2023. Epidemiological information, clinical data, admission classification, ABO blood type, laboratory results, and clinical outcomes were extracted. Univariate analysis was used to compare clinical profiles and risk factors across blood types.ResultsA total of 823 patients (516 males, 307 females) were included. The results showed that Patients with mild/moderate disease at admission exhibited significantly higher cure rates, lower mortality, reduced pneumonia incidence, and younger age compared to severe/critical cases (P < 0.05). Furthermore, Forty-four laboratory indicators—including liver function, renal function, and coagulation parameters—showed significant intergroup differences. Notably, type B blood was associated with a reduced risk of progression to severe/critical disease (P < 0.05), though no significant correlation was observed between blood type and ultimate prognosis.ConclusionNon-B blood types were associated with increased risks of severe/critical COVID-19 progression. Integrating ABO blood typing with clinical laboratory data may improve risk prediction for COVID-19 patients. These findings suggest that ABO blood type could serve as a predictive biomarker for SARS-CoV-2 infection severity. However, further mechanistic studies are required to elucidate the relationship between blood type and disease pathogenesis.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12439-4. Introduction The novel coronavirus pneumonia (Coronavirus Disease 2019, COVID-19) is caused by infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]. COVID-19 spread rapidly across the globe and was declared a pandemic by the World Health Organization (WHO) on March 11, 2020 [2]. As of December 17, 2023, over 772 million confirmed cases and nearly 7 million deaths have been reported worldwide [3]. Its high transmissibility [4]and asymptomatic transmission capacity [5]are considered key drivers of the pandemic. The main symptoms of COVID-19 include fever, headache, cough, fatigue, shortness of breath, olfactory dysfunction and memory impairment. While some patients remain asymptomatic, others progress to severe manifestations, such as dyspnea, hypoxia, acute respiratory distress syndrome, and multi-organ failure [6]. Advanced age and comorbidities (e.g., diabetes, cardiovascular diseases) significantly increase the risk of severe outcomes [7]. Nevertheless, given the limited understanding of COVID-19 pathogenesis and substantial interindividual variability in clinical manifestations and outcomes, researchers continue to explore novel biomarkers for predicting both susceptibility to SARS-CoV-2 infection and the likelihood of severe disease progression [6, 8]. The ABO blood group system discovered in 1901. Since then, research on the relationship between the ABO blood group system and various diseases has never ceased. The correlation between ABO blood type and certain diseases is a widely studied area, with findings suggesting that blood type may influence an individual’s susceptibility or resistance to certain conditions to some extent. In recent years, research on the relationship between ABO blood type and certain viral infections has garnered increasing attention. Growing evidence suggests potential association between ABO blood type and SARS-CoV-2 infection dynamics. However, several key limitations in existing research have led to ambiguous conclusions and a lack of mechanistic understanding: (1) Significant inconsistencies exist across studies, with some reporting that ABO blood group is a factor influencing SARS-CoV-2 infection [9, 10], disease severity [11], and mortality risk [12], while others have failed to confirm such associations [13, 14]. These contradictions highlight issues related to potential confounding factor control or population heterogeneity. (2) There is a substantial lack of exploration into the potential biological mechanisms by which blood group influences clinical phenotypes. In particular, the association with dynamic changes in specific hematological biomarkers (such as red blood cell parameters and coagulation indices) following infection remains underexplored, creating a knowledge gap between “blood group” and “clinical presentation“ [15]. (3) Although some studies suggest a potential protective role for blood group B [16], this finding has not been consistently replicated across different populations. Furthermore, whether blood group B indirectly affects outcomes by reducing the risk of severe disease or directly influences final clinical endpoints (such as mortality) remains controversial and lacks definitive conclusions [17]. This study aims to address the aforementioned issues through a retrospective cohort analysis of 823 hospitalized patients. The innovations of our work are threefold: First, strictly adhering to WHO clinical grading standards, we clearly demonstrate a specific association between blood group B and a reduced risk of progressing to severe/critical illness, moving beyond broad discussions of infection or mortality risk. Second, delving into laboratory parameters, we identified a distinct hematological profile in blood group B patients—characterized by elevated MCV, MCH, and MCHC, alongside decreased APTT and RDW—providing potential mechanistic clues for understanding blood group-related differences in clinical phenotypes. Finally, by clearly establishing that blood group B, while reducing the risk of severe disease, does not affect the final prognosis (mortality/cure rate), our study proposes a crucial new insight: the primary role of ABO blood group may lie in modulating the disease severity process rather than determining the ultimate survival outcome. This finding has important implications for risk stratification and early intervention strategies in clinical practice. The goal of this research is to provide clinical physicians with data to monitor changes in the clinical characteristics of COVID-19 patients, allowing for early interventions to effectively prevent disease progression to severe cases, thereby improving cure rates and offering insights to enhance the standard of medical care for COVID-19. Materials and methods Study design and participants The study population was derived from all consecutive patients hospitalized with COVID-19 at our institution between December 1, 2022, and January 31, 2023. This specific context, immediately following the discontinuation of China’s dynamic zero-COVID policy, ensured that the enrolled cases represented their first documented SARS-CoV-2 infection. Our study aimed to include all eligible patients admitted consecutively during the observation period. The final cohort consisted of those who met all inclusion criteria: (1) adult age (≥ 18 years), (2) laboratory-confirmed SARS-CoV-2 infection via RT-PCR, (3) completion of a full vaccination course prior to observation, (4) a documented ABO blood group, and (5) a final outcome of discharge or death with complete medical records. Patients were excluded for: (1) age < 18 years, (2) missing ABO blood type, (3) incomplete medical records, or (4) transfer to/from another hospital or not being discharged by the end of the observation period. In this study, upon admission, patients are informed in the “Admission Notice” that their medical case information and health data will be utilized for scientific research. Patients with mild conditions provide their own consent, whereas those with severe conditions grant informed consent through their authorized family members. Written consent was obtained from each patient, and the study received approval from the Ethics Committee of the First Affiliated Hospital of Fujian Medical University. The Ethics Committee Approval Number is: MTCA, ECFAH of FMU [2015] No. 084 − 2. Methods Data collection was conducted via the hospital’s electronic medical record system, with the relevant data compiled into electronic spreadsheets and reviewed by senior physicians. The information gathered included patients’ age, sex, length of hospital stay, clinical classification upon admission, pneumonia status, laboratory test results, and prognosis. Patients were categorized into four groups—mild, moderate, severe, and critical—based on the clinical classification at admission, following the guidelines and standards set by the World Health Organization (WHO) for COVID-19 [18]. Furthermore, patients were classified by blood type into A, B, O, and AB groups. We will describe and compare these characteristics across the different patient groups. Statistical methods Statistical differences were evaluated using one-way analysis of variance (ANOVA), the chi-squared test (with Fisher’s exact test employed when necessary), logistic regression, and Cox regression. These analyses were conducted using IBM SPSS Statistics software (Version 22.0.0; IBM, Armonk, New York, USA) and GraphPad Prism 9.0 (GraphPad Software, USA). All P values were two-tailed, with P < 0.05 considered statistically significant. Results Clinical characteristics of COVID-19 patients in this study A total of 823 hospitalized patients with confirmed COVID-19 were included in this study. Based on the World Health Organization (WHO) guidelines and standards for COVID-19 [18], these 823 patients were classified into clinical groups: the general group (n = 593, mild/moderate), the severe group (n = 131, severe), the critical group (n = 99, critical), and the severe/critical group (n = 230, severe/critical). The study analyzed the differences between the general group and the severe and critical groups (P1), as well as between the general group and the severe/critical group (P2). The results showed that the proportion of patients with underlying conditions in the severe, critical, and severe/critical groups was significantly higher than that in the general group (both P1 and P2 < 0.05), as detailed in (Fig. 1). Fig. 1Characteristics of the distribution of underlying diseases in different clinical subgroups of COVID-19 patients Note. (A)P1, general group vs. severe group vs. critically ill group; P2, general group vs. critically ill group. (B) Percentage of patients in the general group with each type of underlying disease. (C) Percentage of patients in the severe group with each type of underlying disease. (D) Percentage of patients in the critical group with each type of underlying disease Characteristics of the distribution of underlying diseases in different clinical subgroups of COVID-19 patients Note. (A)P1, general group vs. severe group vs. critically ill group; P2, general group vs. critically ill group. (B) Percentage of patients in the general group with each type of underlying disease. (C) Percentage of patients in the severe group with each type of underlying disease. (D) Percentage of patients in the critical group with each type of underlying disease Regarding gender and blood type, there were no significant differences in clinical grouping among COVID-19 patients of different sexes and blood types (both P1 and P2 > 0.05). In terms of clinical outcomes, the cure rate in the general group was significantly higher than that in the severe, critical, and severe/critical groups, while the mortality rate was significantly lower in the general group compared to the latter, with statistical significance (both P1 and P2 < 0.05). Furthermore, the analysis of clinical comorbidities indicated that the severity of illness was associated with a higher proportion of patients who developed pneumonia (both P1 and P2 < 0.05). In terms of age, the average age of the general group was significantly lower than that of the severe, critical, and severe/critical groups (both P1 and P2 < 0.05), suggesting that middle-aged and older patients are at a higher risk of progressing to severe or critical illness. This highlights the need for increased clinical attention and intervention for infected individuals in this age group. Detailed data can be found in (Table 1). Table 1Clinical groups of patients with clinical characteristics and blood index resultsClinical GroupsGeneral(mild/moderate)n = 593Severe(severe)n = 131Critical(Critical)n = 99Critically ill(severe/critical)n = 230P1P2Gender0.1990.083 Male3619065155 Female232413475Blood Type0.3130.194 A157392463 B150251843 AB426915 O2446148109Outcomes < 0.0001 < 0.0001 cure248222345 uncured3356541106 dead10443579Presence/Absence of pneumonia < 0.0001 < 0.0001 Yes16813199230 No425000Age59.18 ± 17.2969.05 ± 15.1368.19 ± 14.9468.68 ± 15.09 < 0.0001 < 0.0001 PT(s)(9.8–12.9)13.05 ± 4.4914.33 ± 3.4013.90 ± 2.4514.14 ± 3.03 0.002 0.001 PT-INR1.10 ± 0.211.26 ± 0.341.22 ± 0.241.24 ± 0.30 < 0.0001 < 0.0001 APTT(s)(21.1–36.5)33.75 ± 9.1439.39 ± 13.0737.81 ± 14.4238.71 ± 13.66 < 0.0001 < 0.0001 Fg(g/L)(1.8–3.5)3.76 ± 1.444.17 ± 1.764.61 ± 1.974.35 ± 1.87 < 0.0001 < 0.0001 TT(s)(14.0–21.0)17.83 ± 2.5118.83 ± 7.1418.90 ± 9.1818.86 ± 8.07 0.021 0.058WBC(109/L)(3.5–9.5)7.33 ± 4.268.90 ± 6.169.77 ± 4.629.28 ± 5.55 < 0.0001 < 0.0001 %NEUT(%)(40.0–75.0)66.33 ± 13.6478.79 ± 11.9281.64 ± 11.2580.02 ± 11.70 < 0.0001 < 0.0001 #NEUT(109/L)(1.8–6.3)5.02 ± 3.247.19 ± 4.818.23 ± 4.467.64 ± 4.68 < 0.0001 < 0.0001 %LYMPH(%)(20.0–50.0)22.33 ± 11.4912.86 ± 8.8110.46 ± 8.4111.82 ± 8.70 < 0.0001 < 0.0001 #LYMPH(109/L)(1.1–3.2)1.55 ± 2.660.94 ± 0.790.84 ± 0.550.90 ± 0.69 0.001 0.0002 %MONO(%)(3.0–10.0)6.01 ± 2.275.06 ± 2.334.89 ± 2.824.99 ± 2.54 < 0.0001 < 0.0001 #MONO(109/L)(0.1–0.6)0.41 ± 0.200.42 ± 0.320.44 ± 0.280.43 ± 0.310.4390.400%EO(%)(0.4-8.0)2.05 ± 2.010.91 ± 1.760.88 ± 2.220.89 ± 1.97 < 0.0001 < 0.0001 #EO(109/L)(0.02–0.52)0.13 ± 0.160.08 ± 0.260.06 ± 0.160.07 ± 0.22 < 0.0001 < 0.0001 %BASO(%)(0-0.1.0)0.61 ± 0.550.46 ± 0.890.46 ± 0.760.46 ± 0.83 0.008 0.002 #BASO(109/L)(0-0.06)0.04 ± 0.070.06 ± 0.230.05 ± 0.130.05 ± 0.200.5030.471%LUC(%)(0–7.0)2.70 ± 2.172.06 ± 2.791.78 ± 1.401.94 ± 2.30 < 0.0001 < 0.0001 #LUC(109/L)(0-0.50)0.18 ± 0.230.25 ± 1.370.16 ± 0.210.21 ± 1.050.3960.634RBC(1012/L)(3.8–5.1)4.07 ± 0.853.59 ± 0.913.72 ± 0.903.64 ± 0.91 < 0.0001 < 0.0001 HGB(g/l)(115–150)121.72 ± 24.43107.81 ± 28.13110.16 ± 24.73109.12 ± 26.70 < 0.0001 < 0.0001 HCT (0.35–0.45)0.37 ± 0.070.33 ± 0.080.34 ± 0.070.33 ± 0.08 < 0.0001 < 0.0001 MCV(fL)(82–100)91.69 ± 7.6091.96 ± 8.6091.30 ± 8.0691.68 ± 8.360.8150.978MCH(Pg)(27.0–34.0)30.12 ± 2.9730.20 ± 3.1430.05 ± 2.8330.13 ± 3.010.9350.966MCHC(g/l)(316–354)328.21 ± 14.32327.91 ± 17.45329.36 ± 16.30328.53 ± 16.940.7400.796RDW(%)(11.7–15.3)14.55 ± 2.1615.13 ± 2.7614.69 ± 2.0314.94 ± 2.48 0.030 0.011 PLT(109/L)(125–350)242.94 ± 118.94196.60 ± 99.60207.26 ± 106.54201.19 ± 102.55 < 0.0001 < 0.0001 MPV(fL)(6.5–12.0)8.88 ± 1.249.62 ± 1.349.39 ± 1.549.52 ± 1.43 < 0.0001 < 0.0001 PDW(fL)(15–17)51.37 ± 9.1054.26 ± 10.3454.67 ± 9.5954.44 ± 10.00 0.0001 < 0.0001 PCT (%)(0.11–0.28)0.21 ± 0.100.18 ± 0.090.19 ± 0.080.19 ± 0.09 0.004 0.001 MPC(g/l)(198–300)256.16 ± 19.87248.73 ± 19.12249.65 ± 19.79249.12 ± 19.37 < 0.0001 < 0.0001 TBIL(µmol/L)(0–21)11.93 ± 19.5814.24 ± 38.6710.59 ± 13.9012.67 ± 30.580.4580.683DBIL(µmol/L)(0-6.8)6.71 ± 17.899.59 ± 34.745.92 ± 8.558.01 ± 26.820.2990.420IBIL(µmol/L)(0–19.0)5.36 ± 4.884.64 ± 4.785.67 ± 6.584.66 ± 5.620.2110.078TP(g/L)(65.0–85.0)65.27 ± 8.4058.43 ± 8.4658.87 ± 8.3958.62 ± 8.42 < 0.0001 < 0.0001 ALB(g/L)(40.0–55.0)39.21 ± 6.2633.32 ± 6.5333.21 ± 5.8433.27 ± 6.23 < 0.0001 < 0.0001 GLO(g/L)(20–40)26.03 ± 5.9725.11 ± 5.1225.66 ± 5.5825.35 ± 5.310.2430.128A/G1.60 ± 0.881.38 ± 0.371.35 ± 0.381.37 ± 0.37 0.001 0.0001 ALT(U/L)(7–40)27.51 ± 60.9430.00 ± 61.5641.30 ± 103.2934.86 ± 82.150.1700.161AST(U/L)(13–35)29.99 ± 47.0047.31 ± 150.4860.37 ± 157.1552.93 ± 153.19 0.003 0.027 ALT/AST1.00 ± 1.950.79 ± 0.490.76 ± 0.500.78 ± 0.490.2360.091GGT(U/L)(7–45)59.68 ± 113.5151.17 ± 67.7763.49 ± 90.4256.47 ± 78.380.6270.694LDH(U/L)(120–250)222.08 ± 238.91300.47 ± 221.70356.77 ± 277.84324.70 ± 248.43 < 0.0001 < 0.0001 ALP(U/L)(50–135)101.65 ± 113.7585.73 ± 80.8399.97 ± 102.2191.86 ± 90.720.3090.243CK(U/L)(40–200)165.09 ± 722.86350.21 ± 756.26583.68 ± 1694.32450.70 ± 1251.64 < 0.0001 0.001 CKMB(U/L)(< 25)17.62 ± 23.9124.70 ± 41.7431.77 ± 53.9927.74 ± 47.42 < 0.0001 0.002 UREA(mmol/L)(2.6–7.5)6.01 ± 5.4810.25 ± 9.0611.01 ± 8.9310.58 ± 8.99 < 0.0001 < 0.0001 CREA(µmol/L)(41–73)89.04 ± 119.68140.52 ± 202.49143.43 ± 164.59141.77 ± 186.74 < 0.0001 < 0.0001 UREA/CREA0.44 ± 8.900.09 ± 0.040.09 ± 0.420.09 ± 0.040.8380.553UA(µmol/L)(155–357)305.27 ± 115.07315.36 ± 152.69325.85 ± 165.00319.88 ± 157.840.2850.202GLU(mmol/L)(3.90–6.10)6.19 ± 2.738.16 ± 4.589.00 ± 4.708.52 ± 4.64 < 0.0001 < 0.0001 TC(mmol/L)(< 5.18)1.18 ± 0.051.26 ± 0.113.46 ± 1.153.48 ± 1.21 < 0.0001 < 0.0001 TG(mmol/L)(0.34–1.70)1.37 ± 0.771.24 ± 0.691.54 ± 1.631.37 ± 1.19 0.046 0.974HDL-(mmol/L)(> 1.04)1.13 ± 0.390.96 ± 0.400.93 ± 0.350.94 ± 0.38 < 0.0001 < 0.0001 HDL-C/TC (> 0.15)0.28 ± 0.160.28 ± 0.100.28 ± 0.150.28 ± 0.100.9580.784LDL-(mmol/L)(< 3.40)2.71 ± 1.002.04 ± 1.061.99 ± 1.022.02 ± 1.04 < 0.0001 < 0.0001 VLDL-(mmol/L)(< 0.78)0.63 ± 0.350.56 ± 0.310.70 ± 0.740.62 ± 0.54 0.046 0.945APOA1(g/L)(1.2–1.6)1.18 ± 0.340.92 ± 0.350.91 ± 0.330.91 ± 0.34 < 0.0001 < 0.0001 APOB(g/L)(0.6–1.1)0.95 ± 0.290.84 ± 0.320.83 ± 0.310.84 ± 0.31 < 0.0001 < 0.0001 APOA1/APOB1.34 ± 0.551.19 ± 0.571.23 ± 0.651.21 ± 0.60 0.006 0.002 CA(mmol/L)(2.11–2.52)2.21 ± 0.192.05 ± 0.182.06 ± 0.162.06 ± 0.17 < 0.0001 < 0.0001 P(mmol/L)(0.85–1.51)1.15 ± 0.291.08 ± 0.421.10 ± 0.501.09 ± 0.460.0770.074MG(mmol/L)(0.53–1.11)0.96 ± 1.220.93 ± 0.150.93 ± 0.150.93 ± 0.150.9230.691CO2CP(mmol/L)(22–31)25.03 ± 3.4823.86 ± 4.6322.14 ± 5.3623.12 ± 5.02 < 0.0001 < 0.0001 K(mmol/L)(3.50–5.30)5.61 ± 7.206.32 ± 5.975.61 ± 4.896.02 ± 5.530.5470.444NA(mmol/L)(137–147)132.59 ± 30.95125.23 ± 42.34131.38 ± 33.27127.88 ± 38.740.0730.099CL(mmol/L)(99–110)103.88 ± 10.28106.92 ± 14.01105.07 ± 13.13106.13 ± 13.64 0.018 0.025 AG(mmol/L)(8.0–16.0)17.84 ± 20.9623.03 ± 28.6420.80 ± 23.3222.07 ± 26.45 0.042 0.030 GFR(ml/min/1.73 m2)(> 80)83.90 ± 29.2269.01 ± 35.4167.05 ± 36.4968.17 ± 35.81 < 0.0001 < 0.0001 Note. numerical variables are represented using the mean ± standard deviation. P1, general group vs. severe group vs. critical group; P2, general group vs. critically ill group; numerical variables in the table are expressed as “mean ± standard deviation”; indicators are prehospitalization data except for “outcome”; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NT, prothrombin time. INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NEUT, percentage of neutrophils; #NEUT, neutrophil count; %LYMPH, percentage of lymphocytes; #LYMPH, lymphocyte count; %MONO, percentage of mononuclear cells; #MONO, monocyte count. ; #MONO, monocyte count; %EO, eosinophil percentage; #EO, eosinophil count; %BASO, basophil percentage; #BASO, basophil count; %LUC, percentage of unstained macrophages; #LUC, unstained macrophage count; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin volume; MCHC, mean erythrocyte hemoglobin concentration; RDW, erythrocyte distribution width; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width; PCT, platelet specific volume; MPC, mean platelet component concentration; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin-to-globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALT/AST, alanine aminotransferase to aspartate aminotransferase ratio; GGT, gamma-glutaminyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CK, creatine kinase; CKMB, creatine kinase isoenzyme; UREA, urea; CREA, creatinine; UA, uric acid; GLU, glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HDL-C/TC, ratio of high-density lipoprotein cholesterol to total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; APOA1, apolipoprotein A1; APOB, apolipoprotein B; APOA1/APOB, apolipoprotein A1 to apolipoprotein B ratio; CA, calcium; P, phosphorus; MG, magnesium; CO2CP, carbon dioxide binding capacity; K, potassium; NA, sodium; CL, chloride; AG, anion gap; GFR. Glomerular filtration rate Table 1Clinical groups of patients with clinical characteristics and blood index resultsClinical GroupsGeneral(mild/moderate)n = 593Severe(severe)n = 131Critical(Critical)n = 99Critically ill(severe/critical)n = 230P1P2Gender0.1990.083 Male3619065155 Female232413475Blood Type0.3130.194 A157392463 B150251843 AB426915 O2446148109Outcomes < 0.0001 < 0.0001 cure248222345 uncured3356541106 dead10443579Presence/Absence of pneumonia < 0.0001 < 0.0001 Yes16813199230 No425000Age59.18 ± 17.2969.05 ± 15.1368.19 ± 14.9468.68 ± 15.09 < 0.0001 < 0.0001 PT(s)(9.8–12.9)13.05 ± 4.4914.33 ± 3.4013.90 ± 2.4514.14 ± 3.03 0.002 0.001 PT-INR1.10 ± 0.211.26 ± 0.341.22 ± 0.241.24 ± 0.30 < 0.0001 < 0.0001 APTT(s)(21.1–36.5)33.75 ± 9.1439.39 ± 13.0737.81 ± 14.4238.71 ± 13.66 < 0.0001 < 0.0001 Fg(g/L)(1.8–3.5)3.76 ± 1.444.17 ± 1.764.61 ± 1.974.35 ± 1.87 < 0.0001 < 0.0001 TT(s)(14.0–21.0)17.83 ± 2.5118.83 ± 7.1418.90 ± 9.1818.86 ± 8.07 0.021 0.058WBC(109/L)(3.5–9.5)7.33 ± 4.268.90 ± 6.169.77 ± 4.629.28 ± 5.55 < 0.0001 < 0.0001 %NEUT(%)(40.0–75.0)66.33 ± 13.6478.79 ± 11.9281.64 ± 11.2580.02 ± 11.70 < 0.0001 < 0.0001 #NEUT(109/L)(1.8–6.3)5.02 ± 3.247.19 ± 4.818.23 ± 4.467.64 ± 4.68 < 0.0001 < 0.0001 %LYMPH(%)(20.0–50.0)22.33 ± 11.4912.86 ± 8.8110.46 ± 8.4111.82 ± 8.70 < 0.0001 < 0.0001 #LYMPH(109/L)(1.1–3.2)1.55 ± 2.660.94 ± 0.790.84 ± 0.550.90 ± 0.69 0.001 0.0002 %MONO(%)(3.0–10.0)6.01 ± 2.275.06 ± 2.334.89 ± 2.824.99 ± 2.54 < 0.0001 < 0.0001 #MONO(109/L)(0.1–0.6)0.41 ± 0.200.42 ± 0.320.44 ± 0.280.43 ± 0.310.4390.400%EO(%)(0.4-8.0)2.05 ± 2.010.91 ± 1.760.88 ± 2.220.89 ± 1.97 < 0.0001 < 0.0001 #EO(109/L)(0.02–0.52)0.13 ± 0.160.08 ± 0.260.06 ± 0.160.07 ± 0.22 < 0.0001 < 0.0001 %BASO(%)(0-0.1.0)0.61 ± 0.550.46 ± 0.890.46 ± 0.760.46 ± 0.83 0.008 0.002 #BASO(109/L)(0-0.06)0.04 ± 0.070.06 ± 0.230.05 ± 0.130.05 ± 0.200.5030.471%LUC(%)(0–7.0)2.70 ± 2.172.06 ± 2.791.78 ± 1.401.94 ± 2.30 < 0.0001 < 0.0001 #LUC(109/L)(0-0.50)0.18 ± 0.230.25 ± 1.370.16 ± 0.210.21 ± 1.050.3960.634RBC(1012/L)(3.8–5.1)4.07 ± 0.853.59 ± 0.913.72 ± 0.903.64 ± 0.91 < 0.0001 < 0.0001 HGB(g/l)(115–150)121.72 ± 24.43107.81 ± 28.13110.16 ± 24.73109.12 ± 26.70 < 0.0001 < 0.0001 HCT (0.35–0.45)0.37 ± 0.070.33 ± 0.080.34 ± 0.070.33 ± 0.08 < 0.0001 < 0.0001 MCV(fL)(82–100)91.69 ± 7.6091.96 ± 8.6091.30 ± 8.0691.68 ± 8.360.8150.978MCH(Pg)(27.0–34.0)30.12 ± 2.9730.20 ± 3.1430.05 ± 2.8330.13 ± 3.010.9350.966MCHC(g/l)(316–354)328.21 ± 14.32327.91 ± 17.45329.36 ± 16.30328.53 ± 16.940.7400.796RDW(%)(11.7–15.3)14.55 ± 2.1615.13 ± 2.7614.69 ± 2.0314.94 ± 2.48 0.030 0.011 PLT(109/L)(125–350)242.94 ± 118.94196.60 ± 99.60207.26 ± 106.54201.19 ± 102.55 < 0.0001 < 0.0001 MPV(fL)(6.5–12.0)8.88 ± 1.249.62 ± 1.349.39 ± 1.549.52 ± 1.43 < 0.0001 < 0.0001 PDW(fL)(15–17)51.37 ± 9.1054.26 ± 10.3454.67 ± 9.5954.44 ± 10.00 0.0001 < 0.0001 PCT (%)(0.11–0.28)0.21 ± 0.100.18 ± 0.090.19 ± 0.080.19 ± 0.09 0.004 0.001 MPC(g/l)(198–300)256.16 ± 19.87248.73 ± 19.12249.65 ± 19.79249.12 ± 19.37 < 0.0001 < 0.0001 TBIL(µmol/L)(0–21)11.93 ± 19.5814.24 ± 38.6710.59 ± 13.9012.67 ± 30.580.4580.683DBIL(µmol/L)(0-6.8)6.71 ± 17.899.59 ± 34.745.92 ± 8.558.01 ± 26.820.2990.420IBIL(µmol/L)(0–19.0)5.36 ± 4.884.64 ± 4.785.67 ± 6.584.66 ± 5.620.2110.078TP(g/L)(65.0–85.0)65.27 ± 8.4058.43 ± 8.4658.87 ± 8.3958.62 ± 8.42 < 0.0001 < 0.0001 ALB(g/L)(40.0–55.0)39.21 ± 6.2633.32 ± 6.5333.21 ± 5.8433.27 ± 6.23 < 0.0001 < 0.0001 GLO(g/L)(20–40)26.03 ± 5.9725.11 ± 5.1225.66 ± 5.5825.35 ± 5.310.2430.128A/G1.60 ± 0.881.38 ± 0.371.35 ± 0.381.37 ± 0.37 0.001 0.0001 ALT(U/L)(7–40)27.51 ± 60.9430.00 ± 61.5641.30 ± 103.2934.86 ± 82.150.1700.161AST(U/L)(13–35)29.99 ± 47.0047.31 ± 150.4860.37 ± 157.1552.93 ± 153.19 0.003 0.027 ALT/AST1.00 ± 1.950.79 ± 0.490.76 ± 0.500.78 ± 0.490.2360.091GGT(U/L)(7–45)59.68 ± 113.5151.17 ± 67.7763.49 ± 90.4256.47 ± 78.380.6270.694LDH(U/L)(120–250)222.08 ± 238.91300.47 ± 221.70356.77 ± 277.84324.70 ± 248.43 < 0.0001 < 0.0001 ALP(U/L)(50–135)101.65 ± 113.7585.73 ± 80.8399.97 ± 102.2191.86 ± 90.720.3090.243CK(U/L)(40–200)165.09 ± 722.86350.21 ± 756.26583.68 ± 1694.32450.70 ± 1251.64 < 0.0001 0.001 CKMB(U/L)(< 25)17.62 ± 23.9124.70 ± 41.7431.77 ± 53.9927.74 ± 47.42 < 0.0001 0.002 UREA(mmol/L)(2.6–7.5)6.01 ± 5.4810.25 ± 9.0611.01 ± 8.9310.58 ± 8.99 < 0.0001 < 0.0001 CREA(µmol/L)(41–73)89.04 ± 119.68140.52 ± 202.49143.43 ± 164.59141.77 ± 186.74 < 0.0001 < 0.0001 UREA/CREA0.44 ± 8.900.09 ± 0.040.09 ± 0.420.09 ± 0.040.8380.553UA(µmol/L)(155–357)305.27 ± 115.07315.36 ± 152.69325.85 ± 165.00319.88 ± 157.840.2850.202GLU(mmol/L)(3.90–6.10)6.19 ± 2.738.16 ± 4.589.00 ± 4.708.52 ± 4.64 < 0.0001 < 0.0001 TC(mmol/L)(< 5.18)1.18 ± 0.051.26 ± 0.113.46 ± 1.153.48 ± 1.21 < 0.0001 < 0.0001 TG(mmol/L)(0.34–1.70)1.37 ± 0.771.24 ± 0.691.54 ± 1.631.37 ± 1.19 0.046 0.974HDL-(mmol/L)(> 1.04)1.13 ± 0.390.96 ± 0.400.93 ± 0.350.94 ± 0.38 < 0.0001 < 0.0001 HDL-C/TC (> 0.15)0.28 ± 0.160.28 ± 0.100.28 ± 0.150.28 ± 0.100.9580.784LDL-(mmol/L)(< 3.40)2.71 ± 1.002.04 ± 1.061.99 ± 1.022.02 ± 1.04 < 0.0001 < 0.0001 VLDL-(mmol/L)(< 0.78)0.63 ± 0.350.56 ± 0.310.70 ± 0.740.62 ± 0.54 0.046 0.945APOA1(g/L)(1.2–1.6)1.18 ± 0.340.92 ± 0.350.91 ± 0.330.91 ± 0.34 < 0.0001 < 0.0001 APOB(g/L)(0.6–1.1)0.95 ± 0.290.84 ± 0.320.83 ± 0.310.84 ± 0.31 < 0.0001 < 0.0001 APOA1/APOB1.34 ± 0.551.19 ± 0.571.23 ± 0.651.21 ± 0.60 0.006 0.002 CA(mmol/L)(2.11–2.52)2.21 ± 0.192.05 ± 0.182.06 ± 0.162.06 ± 0.17 < 0.0001 < 0.0001 P(mmol/L)(0.85–1.51)1.15 ± 0.291.08 ± 0.421.10 ± 0.501.09 ± 0.460.0770.074MG(mmol/L)(0.53–1.11)0.96 ± 1.220.93 ± 0.150.93 ± 0.150.93 ± 0.150.9230.691CO2CP(mmol/L)(22–31)25.03 ± 3.4823.86 ± 4.6322.14 ± 5.3623.12 ± 5.02 < 0.0001 < 0.0001 K(mmol/L)(3.50–5.30)5.61 ± 7.206.32 ± 5.975.61 ± 4.896.02 ± 5.530.5470.444NA(mmol/L)(137–147)132.59 ± 30.95125.23 ± 42.34131.38 ± 33.27127.88 ± 38.740.0730.099CL(mmol/L)(99–110)103.88 ± 10.28106.92 ± 14.01105.07 ± 13.13106.13 ± 13.64 0.018 0.025 AG(mmol/L)(8.0–16.0)17.84 ± 20.9623.03 ± 28.6420.80 ± 23.3222.07 ± 26.45 0.042 0.030 GFR(ml/min/1.73 m2)(> 80)83.90 ± 29.2269.01 ± 35.4167.05 ± 36.4968.17 ± 35.81 < 0.0001 < 0.0001 Note. numerical variables are represented using the mean ± standard deviation. P1, general group vs. severe group vs. critical group; P2, general group vs. critically ill group; numerical variables in the table are expressed as “mean ± standard deviation”; indicators are prehospitalization data except for “outcome”; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NT, prothrombin time. INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NEUT, percentage of neutrophils; #NEUT, neutrophil count; %LYMPH, percentage of lymphocytes; #LYMPH, lymphocyte count; %MONO, percentage of mononuclear cells; #MONO, monocyte count. ; #MONO, monocyte count; %EO, eosinophil percentage; #EO, eosinophil count; %BASO, basophil percentage; #BASO, basophil count; %LUC, percentage of unstained macrophages; #LUC, unstained macrophage count; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin volume; MCHC, mean erythrocyte hemoglobin concentration; RDW, erythrocyte distribution width; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width; PCT, platelet specific volume; MPC, mean platelet component concentration; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin-to-globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALT/AST, alanine aminotransferase to aspartate aminotransferase ratio; GGT, gamma-glutaminyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CK, creatine kinase; CKMB, creatine kinase isoenzyme; UREA, urea; CREA, creatinine; UA, uric acid; GLU, glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HDL-C/TC, ratio of high-density lipoprotein cholesterol to total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; APOA1, apolipoprotein A1; APOB, apolipoprotein B; APOA1/APOB, apolipoprotein A1 to apolipoprotein B ratio; CA, calcium; P, phosphorus; MG, magnesium; CO2CP, carbon dioxide binding capacity; K, potassium; NA, sodium; CL, chloride; AG, anion gap; GFR. Glomerular filtration rate Clinical groups of patients with clinical characteristics and blood index results Note. numerical variables are represented using the mean ± standard deviation. P1, general group vs. severe group vs. critical group; P2, general group vs. critically ill group; numerical variables in the table are expressed as “mean ± standard deviation”; indicators are prehospitalization data except for “outcome”; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NT, prothrombin time. INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NEUT, percentage of neutrophils; #NEUT, neutrophil count; %LYMPH, percentage of lymphocytes; #LYMPH, lymphocyte count; %MONO, percentage of mononuclear cells; #MONO, monocyte count. ; #MONO, monocyte count; %EO, eosinophil percentage; #EO, eosinophil count; %BASO, basophil percentage; #BASO, basophil count; %LUC, percentage of unstained macrophages; #LUC, unstained macrophage count; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin volume; MCHC, mean erythrocyte hemoglobin concentration; RDW, erythrocyte distribution width; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width; PCT, platelet specific volume; MPC, mean platelet component concentration; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin-to-globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALT/AST, alanine aminotransferase to aspartate aminotransferase ratio; GGT, gamma-glutaminyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CK, creatine kinase; CKMB, creatine kinase isoenzyme; UREA, urea; CREA, creatinine; UA, uric acid; GLU, glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HDL-C/TC, ratio of high-density lipoprotein cholesterol to total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; APOA1, apolipoprotein A1; APOB, apolipoprotein B; APOA1/APOB, apolipoprotein A1 to apolipoprotein B ratio; CA, calcium; P, phosphorus; MG, magnesium; CO2CP, carbon dioxide binding capacity; K, potassium; NA, sodium; CL, chloride; AG, anion gap; GFR. Glomerular filtration rate Analysis of differences in laboratory indicators among COVID-19 patients across various clinical groups This study compared various indicators between the general group and the severe, critical, and severe/critical groups. It was found that the general group had significantly lower levels of multiple indicators, with statistical significance (both P1 and P2 < 0.05). Additionally, reductions in several other indicators were associated with more severe disease, and these indicators also demonstrated statistical significance (both P1 and P2 < 0.05). Detailed data can be found in (Table 1). Distribution characteristics of clinical groups among COVID-19 patients with different blood types To assess the correlation between blood type and clinical classification following COVID-19 infection, this study included 823 patients: 220 with blood type A and 603 with non-A blood types; 193 with blood type B and 630 with non-B blood types; 57 with blood type AB and 766 with non-AB blood types; and 353 with blood type O and 470 with non-O blood types. Through variance analysis, we found a significant difference in clinical classification between patients with blood type B and those with non-B blood types. Patients with blood type B had a relatively lower risk of developing severe or critical illness compared to those with non-B blood types. Detailed data can be found in (Fig. 2). Fig. 2Characteristics of the distribution of clinical subgroups among different blood groups. Note. (A)Distribution of three clinical subgroups, general, severe, and critical, among patients with different blood groups. (B) Distribution of two clinical subgroups, general and critical care, among patients with different blood groups Characteristics of the distribution of clinical subgroups among different blood groups. Note. (A)Distribution of three clinical subgroups, general, severe, and critical, among patients with different blood groups. (B) Distribution of two clinical subgroups, general and critical care, among patients with different blood groups Comparison of clinical characteristics and blood test results between patients with blood type B and those with Non-B blood types Based on the results depicted in (Fig. 2), we conducted a comparative analysis of clinical characteristics and blood test results between COVID-19 patients with blood type B and those with non-B blood types to further explore the differences in other indicators. The results indicated that patients with blood type B had significantly higher levels of MCV (fL), MCH (Pg), and MCHC (g/L), while APTT (s) and RDW (%) levels were significantly lower, with all differences reaching statistical significance (P < 0.05). Regarding comorbidities, there were no significant differences between patients with blood type B and those with non-B blood types (both P1 and P2 > 0.05), as detailed in (Fig. 3). Furthermore, no statistically significant differences were found in comparisons of gender, pneumonia infection status, age, and other blood test indicators. Specific data can be found in (Table 2). Fig. 3Comparison of the prevalence of underlying medical conditions between COVID-19 patients with blood type B and non-B. Note: Comparison of the proportion of patients with underlying medical conditions between blood type B and non-B groups showed no significant difference (55.44% vs. 54.92%, respectively; Chi-square test, P = 0.8989) Comparison of the prevalence of underlying medical conditions between COVID-19 patients with blood type B and non-B. Note: Comparison of the proportion of patients with underlying medical conditions between blood type B and non-B groups showed no significant difference (55.44% vs. 54.92%, respectively; Chi-square test, P = 0.8989) Table 2Comparison of clinical characteristics and blood indices of patients with B and non-B blood groupsGroup B/non-B blood groupB(n = 193)Non-B(n = 630) P Gender0.864 Male120396 Female73234Presence/Absence of pneumonia0.312 Yes87311 No106319Age62.60 ± 17.0861.60 ± 17.290.482PT(s)(9.8–12.9)13.60 ± 7.3213.28 ± 2.490.355PT-INR1.12 ± 0.211.15 ± 0.250.273APTT(s)(21.1–36.5)33.77 ± 8.5535.56 ± 11.40 0.045 Fg(g/L)(1.8–3.5)3.82 ± 1.583.96 ± 1.690.300TT(s)(14.0–21.0)18.01 ± 2.2218.15 ± 5.330.716WBC(109/L)(3.5–9.5)7.65 ± 3.547.94 ± 5.050.457%NEUT(%)(40.0–75.0)69.71 ± 14.7470.29 ± 14.410.626#NEUT(109/L)(1.8–6.3)5.62 ± 3.505.79 ± 3.990.599%LYMPH(%)(20.0–50.0)19.62 ± 11.7919.32 ± 11.770.762#LYMPH(109/L)(1.1–3.2)1.30 ± 0.731.39 ± 2.600.643%MONO(%)(3.0–10.0)5.76 ± 2.685.72 ± 2.300.811#MONO(109/L)(0.1–0.6)0.41 ± 0.210.42 ± 0.240.515%EO(%)(0.4-8.0)1.83 ± 1.931.69 ± 2.110.432#EO(109/L)(0.02–0.52)0.12 ± 0.150.11 ± 0.190.632%BASO(%)(0-0.1.0)0.56 ± 0.370.57 ± 0.710.781#BASO(109/L)(0-0.06)0.04 ± 0.030.05 ± 0.130.453%LUC(%)(0–7.0)2.53 ± 2.302.47 ± 2.210.741#LUC(109/L)(0-0.50)0.16 ± 0.110.19 ± 0.670.528RBC(1012/L)(3.8–5.1)3.91 ± 0.833.96 ± 0.900.510HGB(g/l)(115–150)120.22 ± 25.14117.58 ± 25.860.213HCT (0.35–0.45)0.36 ± 0.070.36 ± 0.080.451MCV(fL)(82–100)93.29 ± 7.3391.20 ± 7.90 0.001 MCH(Pg)(27.0–34.0)30.85 ± 2.6429.91 ± 3.05 0.0001 MCHC(g/l)(316–354)330.61 ± 13.22327.59 ± 15.56 0.008 RDW(%)(11.7–15.3)14.40 ± 1.9714.74 ± 2.33 0.042 PLT(109/L)(125–350)233.37 ± 121.35230.63 ± 114.480.775MPV(fL)(6.5–12.0)9.06 ± 1.399.05 ± 1.300.925PDW(fL)(15–17)52.17 ± 9.3252.25 ± 9.510.918PCT(%) (0.11–0.28)0.20 ± 0.100.20 ± 0.090.763MPC(g/l)(198–300)253.89 ± 18.55254.29 ± 20.400.800TBIL(µmol/L)(0–21)11.68 ± 20.0312.28 ± 24.060.752DBIL(µmol/L)(0-6.8)6.78 ± 17.707.16 ± 21.630.822IBIL(µmol/L)(0–19.0)5.30 ± 6.625.12 ± 4.540.661TP(g/L)(65.0–85.0)62.43 ± 8.2663.71 ± 9.090.080ALB(g/L)(40.0–55.0)37.01 ± 6.3337.71 ± 6.920.205GLO(g/L)(20–40)25.33 ± 5.8326.00 ± 5.780.160A/G1.62 ± 1.451.51 ± 0.390.096ALT(U/L)(7–40)34.00 ± 100.1328.21 ± 53.830.300AST(U/L)(13–35)41.32 ± 134.5334.89 ± 72.290.390ALT/AST1.12 ± 3.360.88 ± 0.490.317GGT(U/L)(7–45)56.24 ± 81.4459.56 ± 111.080.700LDH(U/L)(120–250)243.51 ± 173.40252.98 ± 264.130.640ALP(U/L)(50–135)93.68 ± 93.90100.52 ± 111.790.441CK(U/L)(40–200)319.33 ± 1276.50222.11 ± 764.220.316CKMB(U/L)(< 25)19.10 ± 33.5020.87 ± 32.260.511UREA(mmol/L)(2.6–7.5)7.28 ± 7.477.29 ± 6.700.996CREA(µmol/L)(41–73)96.97 ± 107.08105.86 ± 152.940.452UREA/CREA1.20 ± 15.600.08 ± 0.030.320UA(µmol/L)(155–357)311.90 ± 129.08308.57 ± 128.450.753GLU(mmol/L)(3.90–6.10)7.03 ± 4.236.78 ± 3.290.386TC(mmol/L)(< 5.18)4.06 ± 1.174.06 ± 1.260.937TG(mmol/L)(0.34–1.70)1.32 ± 0.781.39 ± 0.950.397HDL-C(mmol/L)(> 1.04)1.10 ± 0.381.08 ± 0.400.588HDL-C/TC (> 0.15)0.30 ± 0.250.27 ± 0.090.188LDL-C(mmol/L)(< 3.40)2.55 ± 1.032.51 ± 1.070.613VLDL-C(mmol/L)(< 0.78)0.61 ± 0.360.63 ± 0.430.465APOA1(g/L)(1.2–1.6)1.11 ± 0.351.10 ± 0.360.936APOB(g/L)(0.6–1.1)0.91 ± 0.300.91 ± 0.300.994APOA1/APOB1.34 ± 0.671.30 ± 0.540.425CA(mmol/L)(2.11–2.52)2.16 ± 0.182.17 ± 0.200.310P(mmol/L)(0.85–1.51)1.12 ± 0.311.13 ± 0.350.594MG(mmol/L)(0.53–1.11)1.07 ± 2.131.13 ± 0.350.319CO2CP(mmol/L)(22–31)24.11 ± 4.0524.61 ± 4.060.134K(mmol/L)(3.50–5.30)6.56 ± 11.255.47 ± 4.600.191NA(mmol/L)(137–147)128.72 ± 36.62132.05 ± 32.280.226CL(mmol/L)(99–110)104. 58 ± 13.89104.49 ± 10.470.919AG(mmol/L)(8.0–16.0)20.88 ± 25.5318.46 ± 21.740.235GFR(ml/min/1.73 m2)(> 80)78.82 ± 32.1879.71 ± 31.930.735Note. numerical variables are represented using the mean ± standard deviation. P, B group vs. Non-B group; indicators are prehospitalization data; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NT, prothrombin time. INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NEUT, percentage of neutrophils; #NEUT, neutrophil count; %LYMPH, percentage of lymphocytes; #LYMPH, lymphocyte count; %MONO, percentage of mononuclear cells; #MONO, monocyte count. ; #MONO, monocyte count; %EO, eosinophil percentage; #EO, eosinophil count; %BASO, basophil percentage; #BASO, basophil count; %LUC, percentage of unstained macrophages; #LUC, unstained macrophage count; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin volume; MCHC, mean erythrocyte hemoglobin concentration; RDW, erythrocyte distribution width; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width; PCT, platelet specific volume; MPC, mean platelet component concentration; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin-to-globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALT/AST, alanine aminotransferase to aspartate aminotransferase ratio; GGT, gamma-glutaminyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CK, creatine kinase; CKMB, creatine kinase isoenzyme; UREA, urea; CREA, creatinine; UA, uric acid; GLU, glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HDL-C/TC, ratio of high-density lipoprotein cholesterol to total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; APOA1, apolipoprotein A1; APOB, apolipoprotein B; APOA1/APOB, apolipoprotein A1 to apolipoprotein B ratio; CA, calcium; P, phosphorus; MG, magnesium; CO2CP, carbon dioxide binding capacity; K, potassium; NA, sodium; CL, chloride; AG, anion gap; GFR. Glomerular filtration rate Table 2Comparison of clinical characteristics and blood indices of patients with B and non-B blood groupsGroup B/non-B blood groupB(n = 193)Non-B(n = 630) P Gender0.864 Male120396 Female73234Presence/Absence of pneumonia0.312 Yes87311 No106319Age62.60 ± 17.0861.60 ± 17.290.482PT(s)(9.8–12.9)13.60 ± 7.3213.28 ± 2.490.355PT-INR1.12 ± 0.211.15 ± 0.250.273APTT(s)(21.1–36.5)33.77 ± 8.5535.56 ± 11.40 0.045 Fg(g/L)(1.8–3.5)3.82 ± 1.583.96 ± 1.690.300TT(s)(14.0–21.0)18.01 ± 2.2218.15 ± 5.330.716WBC(109/L)(3.5–9.5)7.65 ± 3.547.94 ± 5.050.457%NEUT(%)(40.0–75.0)69.71 ± 14.7470.29 ± 14.410.626#NEUT(109/L)(1.8–6.3)5.62 ± 3.505.79 ± 3.990.599%LYMPH(%)(20.0–50.0)19.62 ± 11.7919.32 ± 11.770.762#LYMPH(109/L)(1.1–3.2)1.30 ± 0.731.39 ± 2.600.643%MONO(%)(3.0–10.0)5.76 ± 2.685.72 ± 2.300.811#MONO(109/L)(0.1–0.6)0.41 ± 0.210.42 ± 0.240.515%EO(%)(0.4-8.0)1.83 ± 1.931.69 ± 2.110.432#EO(109/L)(0.02–0.52)0.12 ± 0.150.11 ± 0.190.632%BASO(%)(0-0.1.0)0.56 ± 0.370.57 ± 0.710.781#BASO(109/L)(0-0.06)0.04 ± 0.030.05 ± 0.130.453%LUC(%)(0–7.0)2.53 ± 2.302.47 ± 2.210.741#LUC(109/L)(0-0.50)0.16 ± 0.110.19 ± 0.670.528RBC(1012/L)(3.8–5.1)3.91 ± 0.833.96 ± 0.900.510HGB(g/l)(115–150)120.22 ± 25.14117.58 ± 25.860.213HCT (0.35–0.45)0.36 ± 0.070.36 ± 0.080.451MCV(fL)(82–100)93.29 ± 7.3391.20 ± 7.90 0.001 MCH(Pg)(27.0–34.0)30.85 ± 2.6429.91 ± 3.05 0.0001 MCHC(g/l)(316–354)330.61 ± 13.22327.59 ± 15.56 0.008 RDW(%)(11.7–15.3)14.40 ± 1.9714.74 ± 2.33 0.042 PLT(109/L)(125–350)233.37 ± 121.35230.63 ± 114.480.775MPV(fL)(6.5–12.0)9.06 ± 1.399.05 ± 1.300.925PDW(fL)(15–17)52.17 ± 9.3252.25 ± 9.510.918PCT(%) (0.11–0.28)0.20 ± 0.100.20 ± 0.090.763MPC(g/l)(198–300)253.89 ± 18.55254.29 ± 20.400.800TBIL(µmol/L)(0–21)11.68 ± 20.0312.28 ± 24.060.752DBIL(µmol/L)(0-6.8)6.78 ± 17.707.16 ± 21.630.822IBIL(µmol/L)(0–19.0)5.30 ± 6.625.12 ± 4.540.661TP(g/L)(65.0–85.0)62.43 ± 8.2663.71 ± 9.090.080ALB(g/L)(40.0–55.0)37.01 ± 6.3337.71 ± 6.920.205GLO(g/L)(20–40)25.33 ± 5.8326.00 ± 5.780.160A/G1.62 ± 1.451.51 ± 0.390.096ALT(U/L)(7–40)34.00 ± 100.1328.21 ± 53.830.300AST(U/L)(13–35)41.32 ± 134.5334.89 ± 72.290.390ALT/AST1.12 ± 3.360.88 ± 0.490.317GGT(U/L)(7–45)56.24 ± 81.4459.56 ± 111.080.700LDH(U/L)(120–250)243.51 ± 173.40252.98 ± 264.130.640ALP(U/L)(50–135)93.68 ± 93.90100.52 ± 111.790.441CK(U/L)(40–200)319.33 ± 1276.50222.11 ± 764.220.316CKMB(U/L)(< 25)19.10 ± 33.5020.87 ± 32.260.511UREA(mmol/L)(2.6–7.5)7.28 ± 7.477.29 ± 6.700.996CREA(µmol/L)(41–73)96.97 ± 107.08105.86 ± 152.940.452UREA/CREA1.20 ± 15.600.08 ± 0.030.320UA(µmol/L)(155–357)311.90 ± 129.08308.57 ± 128.450.753GLU(mmol/L)(3.90–6.10)7.03 ± 4.236.78 ± 3.290.386TC(mmol/L)(< 5.18)4.06 ± 1.174.06 ± 1.260.937TG(mmol/L)(0.34–1.70)1.32 ± 0.781.39 ± 0.950.397HDL-C(mmol/L)(> 1.04)1.10 ± 0.381.08 ± 0.400.588HDL-C/TC (> 0.15)0.30 ± 0.250.27 ± 0.090.188LDL-C(mmol/L)(< 3.40)2.55 ± 1.032.51 ± 1.070.613VLDL-C(mmol/L)(< 0.78)0.61 ± 0.360.63 ± 0.430.465APOA1(g/L)(1.2–1.6)1.11 ± 0.351.10 ± 0.360.936APOB(g/L)(0.6–1.1)0.91 ± 0.300.91 ± 0.300.994APOA1/APOB1.34 ± 0.671.30 ± 0.540.425CA(mmol/L)(2.11–2.52)2.16 ± 0.182.17 ± 0.200.310P(mmol/L)(0.85–1.51)1.12 ± 0.311.13 ± 0.350.594MG(mmol/L)(0.53–1.11)1.07 ± 2.131.13 ± 0.350.319CO2CP(mmol/L)(22–31)24.11 ± 4.0524.61 ± 4.060.134K(mmol/L)(3.50–5.30)6.56 ± 11.255.47 ± 4.600.191NA(mmol/L)(137–147)128.72 ± 36.62132.05 ± 32.280.226CL(mmol/L)(99–110)104. 58 ± 13.89104.49 ± 10.470.919AG(mmol/L)(8.0–16.0)20.88 ± 25.5318.46 ± 21.740.235GFR(ml/min/1.73 m2)(> 80)78.82 ± 32.1879.71 ± 31.930.735Note. numerical variables are represented using the mean ± standard deviation. P, B group vs. Non-B group; indicators are prehospitalization data; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NT, prothrombin time. INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NEUT, percentage of neutrophils; #NEUT, neutrophil count; %LYMPH, percentage of lymphocytes; #LYMPH, lymphocyte count; %MONO, percentage of mononuclear cells; #MONO, monocyte count. ; #MONO, monocyte count; %EO, eosinophil percentage; #EO, eosinophil count; %BASO, basophil percentage; #BASO, basophil count; %LUC, percentage of unstained macrophages; #LUC, unstained macrophage count; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin volume; MCHC, mean erythrocyte hemoglobin concentration; RDW, erythrocyte distribution width; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width; PCT, platelet specific volume; MPC, mean platelet component concentration; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin-to-globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALT/AST, alanine aminotransferase to aspartate aminotransferase ratio; GGT, gamma-glutaminyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CK, creatine kinase; CKMB, creatine kinase isoenzyme; UREA, urea; CREA, creatinine; UA, uric acid; GLU, glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HDL-C/TC, ratio of high-density lipoprotein cholesterol to total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; APOA1, apolipoprotein A1; APOB, apolipoprotein B; APOA1/APOB, apolipoprotein A1 to apolipoprotein B ratio; CA, calcium; P, phosphorus; MG, magnesium; CO2CP, carbon dioxide binding capacity; K, potassium; NA, sodium; CL, chloride; AG, anion gap; GFR. Glomerular filtration rate Comparison of clinical characteristics and blood indices of patients with B and non-B blood groups Note. numerical variables are represented using the mean ± standard deviation. P, B group vs. Non-B group; indicators are prehospitalization data; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NT, prothrombin time. INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; Fg, fibrinogen; TT, prothrombin time; WBC, white blood cell; %NEUT, percentage of neutrophils; #NEUT, neutrophil count; %LYMPH, percentage of lymphocytes; #LYMPH, lymphocyte count; %MONO, percentage of mononuclear cells; #MONO, monocyte count. ; #MONO, monocyte count; %EO, eosinophil percentage; #EO, eosinophil count; %BASO, basophil percentage; #BASO, basophil count; %LUC, percentage of unstained macrophages; #LUC, unstained macrophage count; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean erythrocyte volume; MCH, mean erythrocyte hemoglobin volume; MCHC, mean erythrocyte hemoglobin concentration; RDW, erythrocyte distribution width; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width; PCT, platelet specific volume; MPC, mean platelet component concentration; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; TP, total protein; ALB, albumin; GLO, globulin; A/G, albumin-to-globulin ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALT/AST, alanine aminotransferase to aspartate aminotransferase ratio; GGT, gamma-glutaminyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CK, creatine kinase; CKMB, creatine kinase isoenzyme; UREA, urea; CREA, creatinine; UA, uric acid; GLU, glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; HDL-C/TC, ratio of high-density lipoprotein cholesterol to total cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; APOA1, apolipoprotein A1; APOB, apolipoprotein B; APOA1/APOB, apolipoprotein A1 to apolipoprotein B ratio; CA, calcium; P, phosphorus; MG, magnesium; CO2CP, carbon dioxide binding capacity; K, potassium; NA, sodium; CL, chloride; AG, anion gap; GFR. Glomerular filtration rate Comparison of prognosis between patients with blood type B and those with non-B blood types Based on the results presented in (Tables 1, 2 and 3), as well as (Figs. 1, 2 and 3), we conducted an analysis to compare the prognostic differences between patients with type B blood and those with non-type B blood following COVID-19 infection. The results indicated no significant difference in clinical outcomes between the two groups, with a P-value of 0.7615. When comparing the total number of deaths, both overall (including patients with and without pneumonia) and specifically for those with and without pneumonia, we found no significant differences between B-type and non-B-type patients. The P-values for total death count, deaths among pneumonia patients, and deaths among non-pneumonia patients were 0.744, 0.578, and 0.459, respectively. Additionally, when analyzing the cumulative number of recoveries among patients with and without pneumonia, there were similarly no significant differences in total recoveries (including both pneumonia and non-pneumonia patients), recoveries among pneumonia patients, and recoveries among non-pneumonia patients, with P-values of 0.817, 0.304, and 0.942, respectively. These findings suggest that blood type B does not appear to influence the prognosis of COVID-19 patients. Detailed data can be seen in (Fig. 4). Table 3Risk factors associated with the prognosis of COVID-19 patientsCharateristicsTotal(N)OR(95%CI)P(value)Type A blood2201.985(0.737–5.345)0.175Type B blood1931.270(0.468–3.445)0.639Type O blood3531.590(0.625–4.044)0.330Type AB blood571.0Age0.059 ≤ 451214.197(0.947–18.597) > 457021.0Gender0.268 Male5160.743(0.440–1.256) Female3071.0Hospitalization Days0.013* ≤ 306550.478(0.267–0.856) > 301681.0Clinical group< 0.001* General5939.119(5.244–15.858) Critically ill2301.0Presence/Absence of pneumonia0.001* No4252.683(1.473–4.886) Yes3981.0Underlying disease0.063 No3701.692(0.971–2.947) Yes4531.0 Table 3Risk factors associated with the prognosis of COVID-19 patientsCharateristicsTotal(N)OR(95%CI)P(value)Type A blood2201.985(0.737–5.345)0.175Type B blood1931.270(0.468–3.445)0.639Type O blood3531.590(0.625–4.044)0.330Type AB blood571.0Age0.059 ≤ 451214.197(0.947–18.597) > 457021.0Gender0.268 Male5160.743(0.440–1.256) Female3071.0Hospitalization Days0.013* ≤ 306550.478(0.267–0.856) > 301681.0Clinical group< 0.001* General5939.119(5.244–15.858) Critically ill2301.0Presence/Absence of pneumonia0.001* No4252.683(1.473–4.886) Yes3981.0Underlying disease0.063 No3701.692(0.971–2.947) Yes4531.0 Risk factors associated with the prognosis of COVID-19 patients Fig. 4Comparison of prognosis between patients with B and non-B blood groups. Note: Kaplan-Meier curves compare the 30-day cumulative incidence of clinical events between patients with blood type B and non-B blood types. (A) Stacked bar chart shows the distribution of final clinical outcomes (cured, uncured, dead) between the two blood groups. (B-D) Cumulative mortality curves for the (B) total cohort, (C) pneumonia subgroup, and (D) non-pneumonia subgroup. No significant difference was found between blood type B and non-B groups (all log-rank P > 0.05). (E-G) Cumulative clinical cure curves for the (E) total cohort, (F) pneumonia subgroup, and (G) non-pneumonia subgroup. No significant difference was found between blood type B and non-B groups (all log-rank P > 0.05). HR, Hazard ratio Comparison of prognosis between patients with B and non-B blood groups. Note: Kaplan-Meier curves compare the 30-day cumulative incidence of clinical events between patients with blood type B and non-B blood types. (A) Stacked bar chart shows the distribution of final clinical outcomes (cured, uncured, dead) between the two blood groups. (B-D) Cumulative mortality curves for the (B) total cohort, (C) pneumonia subgroup, and (D) non-pneumonia subgroup. No significant difference was found between blood type B and non-B groups (all log-rank P > 0.05). (E-G) Cumulative clinical cure curves for the (E) total cohort, (F) pneumonia subgroup, and (G) non-pneumonia subgroup. No significant difference was found between blood type B and non-B groups (all log-rank P > 0.05). HR, Hazard ratio Discussion Prognostic determinants in COVID-19 patients This retrospective analysis of hospitalized COVID-19 patients identified critical prognostic determinants through comparative evaluation of clinical outcomes. The results revealed significant differences in cure rates, mortality rates, and comorbidities between the general group and the critical group. Younger patients without underlying health conditions exhibited better prognoses in the general group, while the critical group faced higher mortality risks and pneumonia infection rates due to older age and the presence of comorbidities. These findings are consistent with those of other studies [1, 7, 19–21], indicating that age, underlying health conditions, and comorbidities are important factors affecting the prognosis of COVID-19 patients. As age increases, the body’s resistance and immune function decline, leading to a higher risk of chronic diseases such as hypertension and diabetes. Additionally, the prevalence of smoking and alcohol consumption is higher among men than women, which contributes to more severe outcomes in elderly males following SARS-CoV-2 infection. Therefore, special attention should be given to this demographic. Furthermore, a deeper exploration of the risk factors associated with critical cases of COVID-19 can enhance the success rate of treatment. Research indicates that advanced age (over 60 years) and the presence of underlying health conditions (such as hypertension, coronary heart disease, diabetes, and chronic pulmonary diseases) are fundamental risk factors for poor prognosis [22–24]. Therefore, these factors should be considered important indicators when assessing the prognosis of COVID-19 patients. It is crucial to provide more intensive clinical treatment and early intervention for elderly patients and those with severe conditions and comorbidities upon admission, based on clinical classification. Laboratory biomarker dynamics and predictive value in COVID-19 prognosis: mechanistic insights This study identified 44 laboratory indicators significantly different between severe/critical COVID-19 patients and general ones. Specifically, 20 indicators were significantly higher in severe/critical groups. Conversely, 24 indicators were significantly lower. These abnormal changes in early laboratory indicators may serve as warning signs for mild COVID-19 patients converting to severe cases. Some studies [22, 25]have also supported this observation. Therefore, regularly monitoring laboratory indicators in individuals infected with SARS-CoV-2 can assist in timely adjustments to treatment plans, potentially allowing for early intervention in mild patients and preventing the progression of their condition. Severe acute respiratory syndrome coronavirus (SARS-CoV-2) can provoke a systemic inflammatory response, and critically ill COVID-19 patients often exhibit complications such as acute respiratory distress syndrome (ARDS), coagulopathy, and multi-organ dysfunction [26–28]. The virus may enter the lungs via the respiratory tract and affect target organs that express ACE2 (Angiotensin-converting enzyme 2), including the lungs, heart, and kidneys. ACE2 is an enzyme involved in regulating blood pressure and cardiovascular health. This interaction can trigger a cascade of immune responses and cytokine storms [29].In summary, the coagulation abnormalities, inflammatory responses, anemia, and organ dysfunction caused by SARS-CoV-2 infection warrant further investigation into their specific mechanisms. This underscores the importance of timely monitoring laboratory indicators in the precise treatment of COVID-19 patients, allowing for the appropriate selection of medications, assessment of therapeutic efficacy and prognosis. Such measures are crucial to preventing disease deterioration, improving cure rates, and reducing mortality. The advantages of blood type B patients and the potential mechanisms in severe COVID-19 infection This study examined the clinical characteristics of hospitalized patients infected with SARS-CoV-2 based on blood type. The results indicated that patients with type B blood exhibited a significant advantage in terms of severe infection rates compared to non-B blood type patients. This finding suggests a potential association between blood type and the severity of COVID-19. The association between ABO blood type and the severity of COVID-19 is typically examined by comparing the blood type distributions among different patient subgroups. Most studies on this topic aim to uncover the correlation between infection risk and severity, with few specifically assessing the relationship with severity alone. Some studies have reported associations between ABO blood type and the risk of SARS-CoV-2 infection but have failed to describe the connection between blood type and severity [30–33]or have drawn inconclusive links [34, 35]. Furthermore, there is limited existing literature on the specific advantages of patients with type B blood, potentially due to sample size limitations or regional differences. Additionally, this study found that patients with type B blood had significantly higher levels of MCV, MCH, and MCHC compared to non-B blood type patients, while their APTT and RDW levels were significantly lower (P < 0.05). These findings offer new insights into the potential mechanisms by which blood type may influence the COVID-19 infection process. Other studies have not directly explored the relationship between blood indices and blood type, likely due to variations in research design and statistical methods employed. Existing research has indicated an association between ABO blood type and SARS-CoV-2 infection, as well as disease severity [36, 37]. A population cohort study conducted in Canada [35]found that individuals with type O blood had a lower risk of SARS-CoV-2 infection and milder disease symptoms compared to those with types A, B, or AB. Although this study did not find significant differences associated with type O blood, the relatively better clinical outcomes observed in patients with type B blood may reflect specific immune mechanisms linked to this blood type. One research hypothesis [38]suggests that certain blood type antigens may influence the binding of SARS-CoV-2 to host cells, thereby impacting the virus’s infectivity and the severity of the disease. Specifically, patients with type B blood may exhibit differences in inflammatory responses and immune responses. Some studies [10]indicate that blood type can influence the release of cytokines and the activity of immune cells. The higher levels of MCV, MCH, and MCHC observed in type B blood patients may suggest a stronger oxygen-carrying capacity and a better physiological state of the blood. This enhanced capacity could help maintain a relatively stable physiological condition in the face of severe infections, thereby reducing the risk of progression to critical illness. Additionally, the lower levels of APTT and RDW may point to advantages in coagulation and inflammation, further decreasing the likelihood of severe disease development. These findings prompt us to further explore the potential underlying molecular mechanisms. The current scientific consensus suggests that the mechanisms by which ABO blood groups influence COVID-19 severity may involve several aspects. Firstly, blood group antigen-mediated interference with viral entry is an important mechanism. ABO blood group antigens are expressed on respiratory epithelial cells [39], where they may interfere with viral adsorption and internalization either by competitively binding to host cell receptors (such as ACE2) against the viral spike protein or by altering the local cell membrane microenvironment [40, 41]. The specific molecular structure of the blood group B antigen may play a unique role in this interference, reducing the efficiency of viral cell entry. Secondly, pathways related to inflammation and coagulation may be particularly critical. Substantial evidence indicates that individuals with non-O blood groups (including A, B, and AB) have higher baseline levels of von Willebrand factor (vWF) and Factor VIII, placing them in an inherent “pro-thrombotic state [42].” One of the core pathophysiological features of severe COVID-19 is vascular endotheliitis and microthrombosis [43]. Therefore, individuals with blood group B, potentially due to their distinct coagulation and inflammatory regulation network compared to those with blood types A or AB, may more effectively maintain endothelial homeostasis and coagulation balance upon SARS-CoV-2 infection. This could help avoid or mitigate organ injury driven by the “cytokine storm” and thrombotic microangiopathy, which might be a core mechanism underlying the lower severe disease rate observed in blood group B patients. The differences in laboratory parameters such as APTT and RDW observed in blood group B patients in our study provide indirect support for this mechanism. Research observations on the prognosis of blood type B and Non-B patients with COVID-19 Although there were no significant differences between patients with type B and non-B blood types regarding comorbidities, factors such as gender, pneumonia status, and age did not show statistical significance in relation to blood type. This may suggest that certain factors within the study sample had a limited impact on clinical outcomes. Existing literature [44]has also reported similar phenomena, indicating that variations in the distribution of comorbidities and disease progression across different regions and populations may contribute to the observed differences in results. The multivariate logistic regression analysis of prognosis differences among COVID-19 patients with different blood types, after controlling for confounding factors such as age, sex, comorbidities, and presence/absence of pneumonia, found no significant differences in prognosis between the different blood types. Specific data can be found in (Table 3). The comparison of hospital length of stay across blood types also revealed no statistically significant difference (Supplementary Material Figure S1). This study observed in (Fig. 4) that there were no statistically significant differences in the cumulative healing events during hospitalization between pneumonia patients with type B blood and those with non-B blood types. This lack of difference is likely due to significant improvements in the healthcare system’s capacity to treat COVID-19 over the past few years, resulting in more critically ill patients being saved. Additionally, it was noted that the cumulative mortality events during hospitalization for pneumonia patients with type B and non-B blood types were also statistically similar. Future research is needed to determine whether differences in prognosis may emerge with larger sample sizes and extended observation periods. Limitations of the study This study has several limitations that should be considered when interpreting the results. The interpretation of our findings must be contextualized within the specific backdrop of China’s initial Omicron wave, which coincided with significant adjustments in public health policy. During this period, the healthcare system was under substantial strain, and admission criteria were inherently skewed toward patients presenting with more severe symptoms. This particular circumstance may have influenced hospitalization patterns and led to a higher proportion of severe cases in our cohort compared to the actual distribution in a fully open environment, thereby potentially affecting the observed severity rates. Furthermore, this study is characterized by a single-center retrospective design, which may limit the generalizability of the findings and necessitates further validation in multi-center cohorts. Additionally, the relatively short observation period and the lack of Rh blood group data represent other constraints. Importantly, these limitations also highlight valuable avenues for future research, including the implementation of multi-center studies with extended follow-up durations and the incorporation of more comprehensive blood group systems into the analysis. Future considerations In summary, based on the results of this study and the literature reported both domestically and internationally, COVID-19 infection cases can be subjected to early clinical interventions and treatment strategies upon admission by considering factors such as patient age, the presence of pneumonia, early clinical characteristics, and laboratory indicators. It is particularly important to pay special attention to non-B blood type patients, as this may indicate a trend toward severe disease progression that requires close monitoring. Clinicians should make timely judgments and adjust treatment plans based on clinical symptoms, signs, and laboratory test results. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1